1. Home
  2. EMN vs GKOS Comparison

EMN vs GKOS Comparison

Compare EMN & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastman Chemical Company

EMN

Eastman Chemical Company

N/A

Current Price

$65.44

Market Cap

8.3B

Sector

Industrials

ML Signal

N/A

Logo Glaukos Corporation

GKOS

Glaukos Corporation

N/A

Current Price

$238.20

Market Cap

9.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EMN
GKOS
Founded
1920
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
9.7B
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
EMN
GKOS
Price
$65.44
$238.20
Analyst Decision
Buy
Strong Buy
Analyst Count
17
13
Target Price
$75.13
★ $242.46
AVG Volume (30 Days)
1.4M
★ 1.5M
Earning Date
10-29-2026
10-28-2026
Dividend Yield
★ 5.14%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 4.70
N/A
Revenue
★ $8,752,000,000.00
$507,442,000.00
Revenue This Year
$5.36
$53.82
Revenue Next Year
$2.33
$28.60
P/E Ratio
$13.98
★ N/A
Revenue Growth
N/A
★ 32.33
52 Week Low
$56.11
$87.32
52 Week High
$83.47
$255.19

Technical Indicators

Market Signals
Indicator
EMN
GKOS
Relative Strength Index (RSI) 49.40 68.27
Support Level $61.94 $143.30
Resistance Level $71.05 N/A
Average True Range (ATR) 1.75 13.56
MACD 0.06 3.35
Stochastic Oscillator 45.75 81.14

Price Performance

Historical Comparison
EMN
GKOS

About EMN Eastman Chemical Company

Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: